Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript Summary
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript Summary
GAAP net earnings for Q3 2024 reached $38.5 million ($0.69 per diluted share), compared to a net loss of $16 million in Q3 2023.The following is a summary of the Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript:
以下是supernus pharmaceuticals, Inc. (SUPN) 2024年第三季度業績會交流摘要：
Financial Performance:
金融業績：
Supernus Pharmaceuticals reported Total Q3 2024 revenue of $175.7 million, up from $153.9 million in Q3 2023.
Net product sales for Q3 2024 were $170.3 million.
GAAP net earnings for Q3 2024 reached $38.5 million ($0.69 per diluted share), compared to a net loss of $16 million in Q3 2023.
Adjusted operating earnings for Q3 2024 were $67.7 million, up from $37.3 million in Q3 2023.
Supernus Pharmaceuticals報告2024年第三季度總營業收入爲17570萬美元，較2023年第三季度的15390萬美元增長。
2024年第三季度淨產品銷售額爲17030萬美元。
2024年第三季度GAAP淨利潤達到3850萬美元（每股攤薄收益爲0.69美元），而2023年第三季度淨虧損爲1600萬美元。
2024年第三季度調整後營業收入達到6770萬美元，較2023年第三季度的3730萬美元增長。
Business Progress:
業務進展：
The company highlighted the strong performance of growth products, particularly Qelbree, which saw a 68% increase in net sales to $62 million.
FDA acknowledged the resubmission of the new drug application for SPN-830 with a target approval date in early 2025.
Reported positive data from Phase 2a studies for SPN-820 in depression and SPN-817 in epilepsy, with plans for a Phase 2b study set to begin by the end of 2024.
公司強調增長產品的強勁表現，特別是Qelbree，淨銷售額增長68%，達到6200萬美元。
FDA已經確認了SPN-830新藥申請的重新提交，預計在2025年初獲得批准。
報告了SPN-820在抑鬱症和SPN-817在癲癇病的2a期研究的積極數據，並計劃在2024年底開始進行階段20億研究。
Opportunities:
機會：
Growth products Qelbree and GOCOVRI are driving significant revenue and are expected to continue this trend.
Upcoming drug approvals and entry into new therapeutic areas provide opportunities for further revenue growth and market expansion.
增長產品Qelbree和GOCOVRI正在推動巨大的營業收入，並預計將繼續這一趨勢。
即將獲得的藥物批准以及進入新的治療領域爲進一步增加營業收入和擴張市場提供了機會。
Risks:
風險：
Potential risk from market competition and generic entries, noted by the first generic for Oxtellar XR impacting monthly prescription rates.
市場競爭和仿製藥進入帶來的潛在風險被指出，首個Oxtellar XR的仿製藥影響了月度處方率。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
